Literature DB >> 17053816

Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc.

L C Boffa1, G Cutrona, M Cilli, S Matis, G Damonte, M R Mariani, E Millo, M Moroni, S Roncella, F Fedeli, M Ferrarini.   

Abstract

In Burkitt's lymphoma (BL) cells due to a t(8;14) chromosomal translocation c-myc is often placed in proximity to the Emu enhancer of the Ig locus and upregulated. We demonstrated that in BL cells a peptide nucleic acid (PNA), complementary to intronic Emu sequences (PNAEmuwt), specifically blocks the expression of the c-myc oncogene under the Emu enhancer control and inhibits BL cell growth in culture. Here, we investigated whether PNAEmuwt was also able to block tumor growth in SCID mice inoculated with human BL cell lines. After subcutaneous inoculum in mice BL cells reproducibly form tumors. Both pre-treatment of BL cells with PNAEmuwt before inoculum and chronic intravenous administration of PNAEmuwt to mice already inoculated with BL cells selectively caused increased latency of tumor appearance and decreased final tumor size. Tumors from PNAEmuwt-treated animals showed substantial areas of cell necrosis and of c-myc downregulation. Inhibition of tumor growth was specific and was not observed with PNAEmumut carrying sequence mutations and in BL cell lines where the translocated c-myc is not under the control of the Emu enhancer. These data confirm the potential therapeutic value of PNA targeted to regulatory non-coding regions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17053816     DOI: 10.1038/sj.cgt.7701002

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  10 in total

1.  Imaging human pancreatic cancer xenografts by targeting mutant KRAS2 mRNA with [(111)In]DOTA(n)-poly(diamidopropanoyl)(m)-KRAS2 PNA-D(Cys-Ser-Lys-Cys) nanoparticles.

Authors:  Nariman V Amirkhanov; Kaijun Zhang; Mohan R Aruva; Mathew L Thakur; Eric Wickstrom
Journal:  Bioconjug Chem       Date:  2010-04-21       Impact factor: 4.774

2.  Cellular uptake of 2-aminopyridine-modified peptide nucleic acids conjugated with cell-penetrating peptides.

Authors:  Nikita Brodyagin; Yuka Kataoka; Ilze Kumpina; Dennis W McGee; Eriks Rozners
Journal:  Biopolymers       Date:  2021-12-16       Impact factor: 2.240

3.  Pharmacokinetic analysis of polyamide nucleic-acid-cell penetrating peptide conjugates targeted against HIV-1 transactivation response element.

Authors:  Sabyasachi Ganguly; Binay Chaubey; Snehlata Tripathi; Alok Upadhyay; Prasad V S V Neti; Roger W Howell; Virendra Nath Pandey
Journal:  Oligonucleotides       Date:  2008-09

4.  Clinical aspects and therapy of sporadic burkitt lymphoma.

Authors:  Livio Pagano; Morena Caira; Caterina Giovanna Valentini; Luana Fianchi
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-28       Impact factor: 2.576

5.  MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.

Authors:  Annalisa Astolfi; Francesca Vendemini; Milena Urbini; Fraia Melchionda; Riccardo Masetti; Monica Franzoni; Virginia Libri; Salvatore Serravalle; Marco Togni; Giuseppina Paone; Luca Montemurro; Daniela Bressanin; Francesca Chiarini; Alberto M Martelli; Roberto Tonelli; Andrea Pession
Journal:  Oncotarget       Date:  2014-01-15

Review 6.  Chiral peptide nucleic acids with a substituent in the N-(2-aminoethy)glycine backbone.

Authors:  Toru Sugiyama; Atsushi Kittaka
Journal:  Molecules       Date:  2012-12-27       Impact factor: 4.411

Review 7.  Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics.

Authors:  Graham McClorey; Subhashis Banerjee
Journal:  Biomedicines       Date:  2018-05-05

Review 8.  Cell penetrating peptide conjugates of steric block oligonucleotides.

Authors:  Bernard Lebleu; Hong M Moulton; Rachida Abes; Gabriela D Ivanova; Said Abes; David A Stein; Patrick L Iversen; Andrey A Arzumanov; Michael J Gait
Journal:  Adv Drug Deliv Rev       Date:  2007-10-22       Impact factor: 15.470

Review 9.  Delivery of therapeutic oligonucleotides with cell penetrating peptides.

Authors:  Prisca Boisguérin; Sébastien Deshayes; Michael J Gait; Liz O'Donovan; Caroline Godfrey; Corinne A Betts; Matthew J A Wood; Bernard Lebleu
Journal:  Adv Drug Deliv Rev       Date:  2015-03-04       Impact factor: 15.470

10.  Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA.

Authors:  Peter Järver; Thibault Coursindel; Samir El Andaloussi; Caroline Godfrey; Matthew Ja Wood; Michael J Gait
Journal:  Mol Ther Nucleic Acids       Date:  2012-06-12       Impact factor: 10.183

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.